Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization

ABSTRACT: Target therapies based on BRAF and MEK inhibitors (MAPKi) have changed the therapeutic landscape for metastatic melanoma patients bearing mutations in the BRAF kinase. However, the emergence of drug resistance imposes the necessity to conceive novel therapeutic strategies capable to achiev...

Descripción completa

Detalles Bibliográficos
Autores principales: Fattore, Luigi, Malpicci, Debora, Milite, Ciro, Castellano, Sabrina, Sbardella, Gianluca, Botti, Gerardo, Ascierto, Paolo A., Mancini, Rita, Ciliberto, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493390/
https://www.ncbi.nlm.nih.gov/pubmed/32933538
http://dx.doi.org/10.1186/s12964-020-00633-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493390/
https://www.ncbi.nlm.nih.gov/pubmed/32933538
http://dx.doi.org/10.1186/s12964-020-00633-7

Ejemplares similares